

Clinical Trial Protocol

Iranian Registry of Clinical Trials

17 Sep 2026

Evaluation of the effectiveness of amiloride-H for treatment of patients suffer from central serous chorioretinopathy

Protocol summary

Study aim

Evaluation of efficacy of using oral Amiloride-H for treatment of central serous chorioretinopathy

Design

Two arm parallel group randomized clinical trial, double blinded

Settings and conduct

This study will be done in Isfahan Feiz hospital on patient suffering central serous chorioretinopathy. the patient divided in two groups. One group with drug and other with placebo will be following. The patient one and three month after beginning study will be followed and their information such as best corrected visual acuity, central thickness of macula, central thickness of choroid record.

Participants/Inclusion and exclusion criteria

Inclusion criteria: Age greater than 18 and less than 50
Presence of acute central serous choriorethinopathy
Lack of existence of other ophthalmic pathology such as glaucoma and chorioretinitis disease
Exclusion criteria:
Patient dissatisfaction with completion study
No return of patient for following examination

Intervention groups

intervention group includes patients suffer from central serous chorioretinopathy who receive Amiloride-h
control group includes patients suffer from central serous chorioretinopathy who receive placebo

Main outcome variables

Best corrected visual acuity, central thickness of macula, central thickness

General information

Reason for update

Acronym

IRCT registration information

IRCT registration number: **IRCT20190311043009N1**

Registration date: **2019-05-09, 1398/02/19**

Registration timing: **registered_while_recruiting**

Last update: **2019-05-09, 1398/02/19**

Update count: **0**

Registration date

2019-05-09, 1398/02/19

Registrant information

Name

Mohammad hossein Taghdiri

Name of organization / entity

Country

Iran (Islamic Republic of)

Phone

+98 31 3447 6011

Email address

dr.taghdiri@resident.mui.ac.ir

Recruitment status

Recruitment complete

Funding source

Expected recruitment start date

2019-04-04, 1398/01/15

Expected recruitment end date

2019-10-07, 1398/07/15

Actual recruitment start date

empty

Actual recruitment end date

empty

Trial completion date

empty

Scientific title

Evaluation of the effectiveness of amiloride-H for treatment of patients suffer from central serous chorioretinopathy

Public title

effect of amiloride-h in central serous chorioretinopathy

Purpose

Treatment

Inclusion/Exclusion criteria

Inclusion criteria:

Presence of acute central serous chorioretinopathy less than past month
Exclusion criteria:
presence of ophthalmologic pathology same as glaucoma, retinal disease and uveitis use of previous treatment, like as medical, PDT, laser photocoagulation

Age

From **18 years** old to **50 years** old

Gender

Both

Phase

3

Groups that have been masked

- Participant
- Care provider
- Investigator

Sample size

Target sample size: **50**

Randomization (investigator's opinion)

Not randomized

Randomization description

Blinding (investigator's opinion)

Double blinded

Blinding description

In this study all the patient and researcher are blind. The patient know they are in a study but they don't know that they use drug or placebo.

Placebo

Used

Assignment

Parallel

Other design features

Secondary Ids

empty

Ethics committees

1

Ethics committee

Name of ethics committee

Ethics committee of Isfahan University of Medical Sciences

Street address

modares Ave, Feiz hospital

City

Isfahan

Province

Isfahan

Postal code

8174673461

Approval date

2019-03-05, 1397/12/14

Ethics committee reference number

IR.MUI.MED.REC.1397.296

Health conditions studied

1

Description of health condition studied

Central serous chorioretinopathy

ICD-10 code

H35.719

ICD-10 code description

Central serous chorioretinopathy, unspecified eye

Primary outcomes

1

Description

Best corrected visual acuity based on snellen chart

Timepoint

Measurement of best corrected visual acuity of the patient at first and 1, 3 month after beginning treatment

Method of measurement

Snellen chart board

Secondary outcomes

1

Description

Central macular thickness

Timepoint

At first and 1, 3 months after treatment

Method of measurement

Imaging of the retina with use of optical coherence tomography

Intervention groups

1

Description

Intervention group: This group will be treated with Amiloride-h that is combination of Amiloride and Hydrochlorothiazide . This drug exists as 5mg tablet that use one time in day for 3 months after beginning.

Category

Treatment - Drugs

2

Description

Control group: this group will use placebo one time in day for 3 month of beginning.

Category

Placebo

Recruitment centers

1

Recruitment center

Name of recruitment center

Feiz Hospital
Full name of responsible person
Mohammad hossein taghdiri
Street address
Aodarres Ave, Feiz Hospital
City
Isfahan
Province
Isfahan
Postal code
8174673461
Phone
+98 31 3445 2033
Email
dr.taghdiri@resident.mui.ac.ir

Sponsors / Funding sources

1

Sponsor

Name of organization / entity
Esfahan University of Medical Sciences
Full name of responsible person
Shaghayegh haghjuj javanmard
Street address
Hezar jarib Ave
City
Isfahan
Province
Isfahan
Postal code
8174673461
Phone
+98 31 3792 9000
Email
dr.taghdiri@gmail.com
Grant name
Grant code / Reference number
Is the source of funding the same sponsor organization/entity?
Yes
Title of funding source
Esfahan University of Medical Sciences
Proportion provided by this source
100
Public or private sector
Public
Domestic or foreign origin
Domestic
Category of foreign source of funding
empty
Country of origin
Type of organization providing the funding
Academic

Person responsible for general inquiries

Contact

Name of organization / entity
Esfahan University of Medical Sciences
Full name of responsible person

Mohammad hossein Taghdiri
Position
Resident
Latest degree
Medical doctor
Other areas of specialty/work
Ophthalmology
Street address
Modares Ave, feiz hospital
City
Isfahan
Province
Isfahan
Postal code
8174673461
Phone
+98 31 3447 6011
Fax
Email
dr.taghdiri@resident.mui.ac.ir

Person responsible for scientific inquiries

Contact

Name of organization / entity
Esfahan University of Medical Sciences
Full name of responsible person
Ali salehi
Position
Associate professor
Latest degree
Subspecialist
Other areas of specialty/work
Ophthalmology
Street address
Modarres Ave, Feiz hospital
City
Isfahan
Province
Isfahan
Postal code
8174673461
Phone
+98 31 3445 2033
Email
a_salehi@med.mui.ac.ir

Person responsible for updating data

Contact

Name of organization / entity
Esfahan University of Medical Sciences
Full name of responsible person
Mohammad hossein Taghdiri
Position
Resident
Latest degree
Medical doctor
Other areas of specialty/work
Ophthalmology
Street address

Modares Ave, feiz hospital

City

Isfahan

Province

Isfahan

Postal code

8174673461

Phone

+98 31 3447 6011

Fax

Email

dr.taghdiri@resident.mui.ac.ir

Sharing plan

Deidentified Individual Participant Data Set (IPD)

Yes - There is a plan to make this available

Study Protocol

Yes - There is a plan to make this available

Statistical Analysis Plan

Yes - There is a plan to make this available

Informed Consent Form

Yes - There is a plan to make this available

Clinical Study Report

Yes - There is a plan to make this available

Analytic Code

Yes - There is a plan to make this available

Data Dictionary

Yes - There is a plan to make this available

Title and more details about the data/document

Visual acuity in study

When the data will become available and for how long

one year

To whom data/document is available

Valid journals

Under which criteria data/document could be used

Evaluation of study

From where data/document is obtainable

Responsible author

What processes are involved for a request to access data/document

Contact via E-mail

Comments